Key Topics

Benign prostatic hyperplasia (BPH), a common pathology affecting men generally above age of 50, with a negative impact on quality of life, has conventionally been treated by transurethral resection of the prostate (TURP). Over the last couple of decades transurethral laser vaporization has replaced TURP.

Irrespective of the laser source used (Thulium, Holmium, PVP), transurethral laser vaporization remains an invasive procedure. More recently, newer minimally invasive therapies (MITs) have entered the playing field challenging the standard approaches (TURP or transurethral laser vaporization) as  less invasive alternatives to be proposed to patients. Within the field of MITs, EchoLaser SoracteLite™ TPLA (Transperineal Laser Ablation) represents a micro-invasive innovative and painless option treatment, performed without anaesthesia using extremely thin applicators and low energy doses. During this webinar, EchoLaser SoracteLite™ treatment will be presented and discussed, in light of studies completed or underway and real world evidence.